ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
Conditions
Keywords
Inclisiran sodium, ASCVD, LDL-C, HeFH, HoFH
Brief summary
The purpose of this extension study was to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study was a global multicenter study.
Detailed description
This study was an open label, long term extension study in subjects with atherosclerotic cardiovascular disease (ASCVD), ASCVD-risk equivalents (eg, diabetes and familial hypercholesterolemia), or heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C) despite maximum tolerated dose of LDL-C lowering therapies who have completed the inclisiran Phase II trial MDCO-PCS-16-01 (ORION-3; NCT03060577), or any of the following Phase III lipid lowering studies: MDCO-PCS-17-03 (ORION-9; NCT03397121), MDCO-PCS-17-04 (ORION-10; NCT03399370), or MDCO-PCS-17-08 (ORION-11; NCT03400800). The End of Study (EOS) visit in the previous feeder studies was Day 1 in this extension study.The duration that each subject participated in this study was a maximum of 3 years. However, for subjects from the Study ORION-3, the Sponsor decided to end the study prior to completion of their full 3-year of participation. It is recorded in the database as discontinuation was due to Sponsor's decision. In this Phase III extension study, the same study drug of inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) was administered as a single subcutaneous (SC) dose every 180 days from the last dose in previous feeder study (except for subjects newly initiating inclisiran, who received the first two doses 90 days apart) until the end of the study. On Day 1 (EOS visit in the feeder study), subjects from the previous feeder studies received blinded study medication except subjects from Study ORION-3. Subjects who received placebo in the previous Phase III feeder study received blinded inclisiran and subjects who received inclisiran in the previous feeder study received blinded placebo at this visit, so that subjects previously on placebo received the correct dosing regime, i.e. a dose at Day 1, Day 90 and every 180-days thereafter. Subjects previously treated with inclisiran did not need a dose of inclisiran to maintain every 180-dosing regime and therefore, were given placebo in order to maintain the blinding of the feeder study. Subjects that moved over from ORION-3 received the first study medication at Day 90, as this study was already open-label. On Day 90, all subjects received inclisiran sodium 300 mg. This is 180 days after the last injection in the previous feeder study for subjects that received inclisiran and was the second dose of inclisiran for the subjects that received placebo in the feeder study. The EOS visit occurred at Day 1080. This extension study allowed subjects continued access to inclisiran treatment and allowed the collection of additional efficacy and safety data for long-term use beyond the end of the feeder studies.
Interventions
Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Completion on a previously qualifying inclisiran Phase II trial MDCO-PCS-16-01 (ORION-3), or Phase III lipid lowering ORION feeder study \[MDCO-PCS-17-03 (ORION-9), MDCO-PCS-17-4 (ORION-10), or MDCO-PCS-17-08 (ORION-11)\] meaning the subject received the last dose of study drug and completed the final study visit per applicable protocol. 2. On current lipid-lowering therapies (such as a statin and/or ezetimibe) from previous study with no planned medication or dose change during study participation. 3. Willing and able to give informed consent before initiation of any study-related procedures and willing to comply with all required study procedures.
Exclusion criteria
1. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the subject at significant risk \[according to investigator's (or delegate's) judgment\] if he/she participates in the clinical study. 2. An underlying known disease, or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate) might interfere with interpretation of the clinical study results. 3. Severe concomitant noncardiovascular disease that carries the risk of reducing life expectancy to less than 3 years, 4. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained alanine aminotransferase (ALT), aspartate aminotransferase (AST), elevation \>3x the upper limit of normal (ULN), or total bilirubin (TBIL) elevation \>2x ULN at the last recorded visit in the feeder study prior to study entry visit. 5. Females who are pregnant or nursing, or who are of childbearing potential and unwilling to use at least one method of acceptable effective contraception (eg, oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device) for the entire duration of the study. Exemptions from this criterion: 1. Women \>2 years postmenopausal (defined as 1 year or longer since last menstrual period) and more than 55 years of age. 2. Postmenopausal women (as defined above) and less than 55 years of age with a negative pregnancy test within 24 hours of randomization. 3. Women who are surgically sterilized at least 3 months prior to enrollment. 6. Planned use of other investigational medicinal products other than inclisiran or devices during the course of the study. 7. Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to: 1. Subjects who are unable to communicate or to cooperate with the investigator 2. Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study (including subjects whose cooperation is doubtful due to drug abuse or alcohol dependency) 3. Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (eg, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study) 4. Have any medical or surgical condition, which in the opinion of the investigator would put the subject at increased risk from participating in the study 5. Persons directly involved in the conduct of the study. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk | From ORION-8 Day 1 to the end of study (up to 1080 days) | The primary objective of the study is to evaluate the effect of inclisiran treatment on the proportion of subjects achieving prespecified LDL-C targets at end of study (EOS). Target is \<70 mg/dL for atherosclerotic cardiovascular disease (ASCVD) subjects and \<100 mg/dL for ASCVD risk equivalent subjects. Risk equivalent subjects are defined as either type 2 diabetes, familial hypercholesterolemia or a 10-year risk of a cardiovascular event ≥20% as assessed by the Framingham Risk Score or equivalent; without a medical history of coronary heart disease , cerebrovascular disease or peripheral artery disease. |
| Incidence of Treatment-emergent Adverse Events (TEAEs) | From ORION-8 Day 1 to the end of study (up to 1080 days) | Safety assessments include adverse events and serious adverse events until the end of study. End of study visit occured at least 90 days following the last inclisiran dose once a decision was made to end the study (either by the subject, investigator or sponsor). For subjects prematurely and permanently discontinued from study treatment, who were not willing to return within the 90 day timeframe, the EOS visit was scheduled as soon as possible, or if decision to discontinue and not return was made at a specific visit, this visit became the EOS visit. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Absolute Change in LDL-C From the Initial Feeder Study Baseline | Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days) | Absolute change from baseline in low density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran on LDL-C levels. |
| Percentage Change in LDL-C From the Initial Feeder Study Baseline | Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days) | Percentage change from baseline in low density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran on LDL-C levels. |
| Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days) | Absolute change from baseline in total cholesterol, triglycerides and high density lipoprotein cholesterol (HDL-C) was calculated to evaluate the effect of inclisiran on other lipids and lipoproteins. |
| Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days) | Percentage change from baseline in total cholesterol (TC), triglycerides and high density lipoprotein cholesterol (HDL-C) was calculated to evaluate the effect of inclisiran on other lipids and lipoproteins. |
Countries
Canada, Czechia, Denmark, Germany, Hungary, Netherlands, Poland, South Africa, Spain, Sweden, Ukraine, United Kingdom, United States
Participant flow
Recruitment details
268 centers in 13 countries: United States(145), Canada(8), Czechia(4), Denmark(6), Germany(9), Hungary(4), Netherlands(12), Poland(18), South Africa(12), Spain(6), Sweden(3), Ukraine(8), United Kingdom(33)
Pre-assignment details
Participants completed a qualifying Phase II lipid lowering trial \[MDCO-PCS-16-01 (ORION-3)\] or Phase III lipid-lowering ORION feeder study \[MDCO-PCS-17-03 (ORION-9), MDCO-PCS-17-04 (ORION-10), or MDCO-PCS-17-08 (ORION-11) \] meaning the subject received the last dose of study drug and completed the final study visit per applicable protocol.
Participants by arm
| Arm | Count |
|---|---|
| Phase III Inclisiran-Inclisiran Subjects who received inclisiran (actual treatment) in studies ORION-9/ ORION-10/ORION-11 | 1,512 |
| Phase III Placebo-Inclisiran subjects who received placebo (actual treatment) in ORION-9/ORION-10/ORION-11 | 1,478 |
| ORION-3 Rollover Subjects rolling over from ORION-3 Phase II study | 284 |
| Total | 3,274 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 22 | 23 | 0 |
| Overall Study | Death | 80 | 81 | 4 |
| Overall Study | Initiation Of Protocol-Prohibited Approved PCSK9 Inhibitor | 0 | 0 | 1 |
| Overall Study | Lost to Follow-up | 47 | 52 | 1 |
| Overall Study | Other reasons | 34 | 40 | 2 |
| Overall Study | Physician Decision | 7 | 4 | 2 |
| Overall Study | Sponsor's Administrative Decision | 0 | 0 | 272 |
| Overall Study | Withdrew Consent | 77 | 78 | 2 |
Baseline characteristics
| Characteristic | Phase III Placebo-Inclisiran | ORION-3 Rollover | Total | Phase III Inclisiran-Inclisiran |
|---|---|---|---|---|
| Age, Continuous | 64.6 years STANDARD_DEVIATION 9.82 | 67.7 years STANDARD_DEVIATION 9.97 | 64.9 years STANDARD_DEVIATION 9.88 | 64.7 years STANDARD_DEVIATION 9.83 |
| Race/Ethnicity, Customized American Indian/Alaska Native | 2 Participants | 2 Participants | 7 Participants | 3 Participants |
| Race/Ethnicity, Customized Asian | 7 Participants | 3 Participants | 27 Participants | 17 Participants |
| Race/Ethnicity, Customized Black/African American | 78 Participants | 7 Participants | 188 Participants | 103 Participants |
| Race/Ethnicity, Customized Missing | 0 Participants | 1 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Native Hawaiian/Other Pacific Islander | 4 Participants | 0 Participants | 10 Participants | 6 Participants |
| Race/Ethnicity, Customized White | 1387 Participants | 271 Participants | 3041 Participants | 1383 Participants |
| Sex: Female, Male Female | 476 Participants | 100 Participants | 1058 Participants | 482 Participants |
| Sex: Female, Male Male | 1002 Participants | 184 Participants | 2216 Participants | 1030 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 80 / 1,512 | 81 / 1,478 | 4 / 284 | 165 / 3,274 |
| other Total, other adverse events | 1,110 / 1,512 | 1,073 / 1,478 | 169 / 284 | 2,352 / 3,274 |
| serious Total, serious adverse events | 464 / 1,512 | 482 / 1,478 | 43 / 284 | 989 / 3,274 |
Outcome results
Primary
Incidence of Treatment-emergent Adverse Events (TEAEs)
Safety assessments include adverse events and serious adverse events until the end of study. End of study visit occured at least 90 days following the last inclisiran dose once a decision was made to end the study (either by the subject, investigator or sponsor). For subjects prematurely and permanently discontinued from study treatment, who were not willing to return within the 90 day timeframe, the EOS visit was scheduled as soon as possible, or if decision to discontinue and not return was made at a specific visit, this visit became the EOS visit.
Time frame: From ORION-8 Day 1 to the end of study (up to 1080 days)
Population: Safety Population: All ORION-3 rollover subjects who signed the informed consent to Study Orion-8, and all ORION-9/ORION-10/ORION-11 rollover subjects with at least one study drug administration in Study
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase III Inclisiran-Inclisiran | Incidence of Treatment-emergent Adverse Events (TEAEs) | SAEs: Treatment-related | 2 Participants |
| Phase III Inclisiran-Inclisiran | Incidence of Treatment-emergent Adverse Events (TEAEs) | Adverse events :Treatment-related | 133 Participants |
| Phase III Inclisiran-Inclisiran | Incidence of Treatment-emergent Adverse Events (TEAEs) | Fatal SAEs: Treatment-related | 0 Participants |
| Phase III Inclisiran-Inclisiran | Incidence of Treatment-emergent Adverse Events (TEAEs) | Adverse events | 1197 Participants |
| Phase III Inclisiran-Inclisiran | Incidence of Treatment-emergent Adverse Events (TEAEs) | Fatal SAEs | 80 Participants |
| Phase III Inclisiran-Inclisiran | Incidence of Treatment-emergent Adverse Events (TEAEs) | SAEs | 464 Participants |
| Phase III Placebo-Inclisiran | Incidence of Treatment-emergent Adverse Events (TEAEs) | Adverse events | 1170 Participants |
| Phase III Placebo-Inclisiran | Incidence of Treatment-emergent Adverse Events (TEAEs) | Fatal SAEs: Treatment-related | 0 Participants |
| Phase III Placebo-Inclisiran | Incidence of Treatment-emergent Adverse Events (TEAEs) | SAEs: Treatment-related | 2 Participants |
| Phase III Placebo-Inclisiran | Incidence of Treatment-emergent Adverse Events (TEAEs) | SAEs | 482 Participants |
| Phase III Placebo-Inclisiran | Incidence of Treatment-emergent Adverse Events (TEAEs) | Adverse events :Treatment-related | 148 Participants |
| Phase III Placebo-Inclisiran | Incidence of Treatment-emergent Adverse Events (TEAEs) | Fatal SAEs | 81 Participants |
| ORION-3 Rollover | Incidence of Treatment-emergent Adverse Events (TEAEs) | Adverse events | 181 Participants |
| ORION-3 Rollover | Incidence of Treatment-emergent Adverse Events (TEAEs) | Fatal SAEs | 4 Participants |
| ORION-3 Rollover | Incidence of Treatment-emergent Adverse Events (TEAEs) | Adverse events :Treatment-related | 16 Participants |
| ORION-3 Rollover | Incidence of Treatment-emergent Adverse Events (TEAEs) | SAEs | 43 Participants |
| ORION-3 Rollover | Incidence of Treatment-emergent Adverse Events (TEAEs) | SAEs: Treatment-related | 1 Participants |
| ORION-3 Rollover | Incidence of Treatment-emergent Adverse Events (TEAEs) | Fatal SAEs: Treatment-related | 0 Participants |
| Total | Incidence of Treatment-emergent Adverse Events (TEAEs) | SAEs: Treatment-related | 5 Participants |
| Total | Incidence of Treatment-emergent Adverse Events (TEAEs) | Adverse events :Treatment-related | 297 Participants |
| Total | Incidence of Treatment-emergent Adverse Events (TEAEs) | Fatal SAEs | 165 Participants |
| Total | Incidence of Treatment-emergent Adverse Events (TEAEs) | Adverse events | 2548 Participants |
| Total | Incidence of Treatment-emergent Adverse Events (TEAEs) | SAEs | 989 Participants |
| Total | Incidence of Treatment-emergent Adverse Events (TEAEs) | Fatal SAEs: Treatment-related | 0 Participants |
Primary
Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk
The primary objective of the study is to evaluate the effect of inclisiran treatment on the proportion of subjects achieving prespecified LDL-C targets at end of study (EOS). Target is \<70 mg/dL for atherosclerotic cardiovascular disease (ASCVD) subjects and \<100 mg/dL for ASCVD risk equivalent subjects. Risk equivalent subjects are defined as either type 2 diabetes, familial hypercholesterolemia or a 10-year risk of a cardiovascular event ≥20% as assessed by the Framingham Risk Score or equivalent; without a medical history of coronary heart disease , cerebrovascular disease or peripheral artery disease.
Time frame: From ORION-8 Day 1 to the end of study (up to 1080 days)
Population: Safety Population: All ORION-3 rollover subjects who signed the informed consent to Study ORION-8, and all ORION-9/ORION-10/ORION-11 rollover subjects with at least one study drug administration in Study. Only participants with valid LDL-C measurements at Day 1080/EOS were included in the analysis.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Phase III Inclisiran-Inclisiran | Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk | % of ASCVD Risk Equivalent subjects Who Attain Global Lipid Targets of <100 mg/dL at Day 1080 / EOS | 72.56 Percentage of participants |
| Phase III Inclisiran-Inclisiran | Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk | % of ASCVD subjects Who Attain Global Lipid Targets of <70 mg/dL at Day 1080 / EOS | 79.34 Percentage of participants |
| Phase III Inclisiran-Inclisiran | Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk | % of subjects Who Attain Global Lipid Targets at Day 1080 / EOS | 78.18 Percentage of participants |
| Phase III Placebo-Inclisiran | Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk | % of ASCVD Risk Equivalent subjects Who Attain Global Lipid Targets of <100 mg/dL at Day 1080 / EOS | 74.88 Percentage of participants |
| Phase III Placebo-Inclisiran | Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk | % of ASCVD subjects Who Attain Global Lipid Targets of <70 mg/dL at Day 1080 / EOS | 79.96 Percentage of participants |
| Phase III Placebo-Inclisiran | Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk | % of subjects Who Attain Global Lipid Targets at Day 1080 / EOS | 79.07 Percentage of participants |
| ORION-3 Rollover | Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk | % of subjects Who Attain Global Lipid Targets at Day 1080 / EOS | 76.81 Percentage of participants |
| ORION-3 Rollover | Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk | % of ASCVD subjects Who Attain Global Lipid Targets of <70 mg/dL at Day 1080 / EOS | 76.70 Percentage of participants |
| ORION-3 Rollover | Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk | % of ASCVD Risk Equivalent subjects Who Attain Global Lipid Targets of <100 mg/dL at Day 1080 / EOS | 77.00 Percentage of participants |
| Total | Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk | % of ASCVD Risk Equivalent subjects Who Attain Global Lipid Targets of <100 mg/dL at Day 1080 / EOS | 74.33 Percentage of participants |
| Total | Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk | % of ASCVD subjects Who Attain Global Lipid Targets of <70 mg/dL at Day 1080 / EOS | 79.41 Percentage of participants |
| Total | Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk | % of subjects Who Attain Global Lipid Targets at Day 1080 / EOS | 78.43 Percentage of participants |
Secondary
Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C
Absolute change from baseline in total cholesterol, triglycerides and high density lipoprotein cholesterol (HDL-C) was calculated to evaluate the effect of inclisiran on other lipids and lipoproteins.
Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Population: Safety Population: All ORION-3 rollover subjects who signed the informed consent to Study Orion-8, and all ORION-9/ORION-10/ORION-11 rollover subjects with at least one study drug administration in Study
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Phase III Inclisiran-Inclisiran | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline Total Cholesterol (TC) | -59.05 mg/dL |
| Phase III Inclisiran-Inclisiran | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS Total Cholesterol (TC) | -58.48 mg/dL |
| Phase III Inclisiran-Inclisiran | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline Triglycerides | -21.50 mg/dL |
| Phase III Inclisiran-Inclisiran | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS Triglycerides | -19.58 mg/dL |
| Phase III Inclisiran-Inclisiran | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline HDL Cholesterol | 3.37 mg/dL |
| Phase III Inclisiran-Inclisiran | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS HDL Cholesterol | 3.60 mg/dL |
| Phase III Placebo-Inclisiran | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS HDL Cholesterol | 4.39 mg/dL |
| Phase III Placebo-Inclisiran | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline Total Cholesterol (TC) | -0.07 mg/dL |
| Phase III Placebo-Inclisiran | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS Triglycerides | -22.12 mg/dL |
| Phase III Placebo-Inclisiran | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline HDL Cholesterol | 0.59 mg/dL |
| Phase III Placebo-Inclisiran | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS Total Cholesterol (TC) | -57.08 mg/dL |
| Phase III Placebo-Inclisiran | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline Triglycerides | -5.74 mg/dL |
| ORION-3 Rollover | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS Total Cholesterol (TC) | -65.43 mg/dL |
| ORION-3 Rollover | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline Triglycerides | -14.43 mg/dL |
| ORION-3 Rollover | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS HDL Cholesterol | 5.27 mg/dL |
| ORION-3 Rollover | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS Triglycerides | -21.32 mg/dL |
| ORION-3 Rollover | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline Total Cholesterol (TC) | -63.11 mg/dL |
| ORION-3 Rollover | Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline HDL Cholesterol | 3.41 mg/dL |
Secondary
Absolute Change in LDL-C From the Initial Feeder Study Baseline
Absolute change from baseline in low density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran on LDL-C levels.
Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Population: Safety Population: All ORION-3 rollover subjects who signed the informed consent to Study Orion-8, and all ORION-9/ORION-10/ORION-11 rollover subjects with at least one study drug administration in Study
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Phase III Inclisiran-Inclisiran | Absolute Change in LDL-C From the Initial Feeder Study Baseline | ORION-8 Baseline | -55.21 mg/dL |
| Phase III Inclisiran-Inclisiran | Absolute Change in LDL-C From the Initial Feeder Study Baseline | Day 1080 / EOS | -55.81 mg/dL |
| Phase III Placebo-Inclisiran | Absolute Change in LDL-C From the Initial Feeder Study Baseline | ORION-8 Baseline | 0.46 mg/dL |
| Phase III Placebo-Inclisiran | Absolute Change in LDL-C From the Initial Feeder Study Baseline | Day 1080 / EOS | -54.70 mg/dL |
| ORION-3 Rollover | Absolute Change in LDL-C From the Initial Feeder Study Baseline | ORION-8 Baseline | -61.58 mg/dL |
| ORION-3 Rollover | Absolute Change in LDL-C From the Initial Feeder Study Baseline | Day 1080 / EOS | -64.31 mg/dL |
Secondary
Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C
Percentage change from baseline in total cholesterol (TC), triglycerides and high density lipoprotein cholesterol (HDL-C) was calculated to evaluate the effect of inclisiran on other lipids and lipoproteins.
Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Population: Safety Population: All ORION-3 rollover subjects who signed the informed consent to Study Orion-8, and all ORION-9/ORION-10/ORION-11 rollover subjects with at least one study drug administration in Study
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Phase III Inclisiran-Inclisiran | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline Total Cholesterol (TC) | -30.64 Percentage change |
| Phase III Inclisiran-Inclisiran | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS Total Cholesterol (TC) | -29.34 Percentage change |
| Phase III Inclisiran-Inclisiran | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline Triglycerides | -7.84 Percentage change |
| Phase III Inclisiran-Inclisiran | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS Triglycerides | -3.90 Percentage change |
| Phase III Inclisiran-Inclisiran | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline HDL Cholesterol | 9.28 Percentage change |
| Phase III Inclisiran-Inclisiran | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS HDL Cholesterol | 9.91 Percentage change |
| Phase III Placebo-Inclisiran | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS HDL Cholesterol | 11.75 Percentage change |
| Phase III Placebo-Inclisiran | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline Total Cholesterol (TC) | 1.28 Percentage change |
| Phase III Placebo-Inclisiran | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS Triglycerides | -6.85 Percentage change |
| Phase III Placebo-Inclisiran | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline HDL Cholesterol | 3.48 Percentage change |
| Phase III Placebo-Inclisiran | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS Total Cholesterol (TC) | -29.53 Percentage change |
| Phase III Placebo-Inclisiran | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline Triglycerides | 3.03 Percentage change |
| ORION-3 Rollover | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS Total Cholesterol (TC) | -30.44 Percentage change |
| ORION-3 Rollover | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline Triglycerides | -0.20 Percentage change |
| ORION-3 Rollover | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS HDL Cholesterol | 12.16 Percentage change |
| ORION-3 Rollover | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | Day 1080 / EOS Triglycerides | -3.18 Percentage change |
| ORION-3 Rollover | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline Total Cholesterol (TC) | -29.49 Percentage change |
| ORION-3 Rollover | Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C | ORION-8 Baseline HDL Cholesterol | 8.13 Percentage change |
Secondary
Percentage Change in LDL-C From the Initial Feeder Study Baseline
Percentage change from baseline in low density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran on LDL-C levels.
Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Population: Safety Population: All ORION-3 rollover subjects who signed the informed consent to Study Orion-8, and all ORION-9/ORION-10/ORION-11 rollover subjects with at least one study drug administration in Study
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Phase III Inclisiran-Inclisiran | Percentage Change in LDL-C From the Initial Feeder Study Baseline | ORION-8 Baseline | -50.02 Percentage change in LDL-C |
| Phase III Inclisiran-Inclisiran | Percentage Change in LDL-C From the Initial Feeder Study Baseline | Day 1080 / EOS | -48.96 Percentage change in LDL-C |
| Phase III Placebo-Inclisiran | Percentage Change in LDL-C From the Initial Feeder Study Baseline | ORION-8 Baseline | 3.10 Percentage change in LDL-C |
| Phase III Placebo-Inclisiran | Percentage Change in LDL-C From the Initial Feeder Study Baseline | Day 1080 / EOS | -49.69 Percentage change in LDL-C |
| ORION-3 Rollover | Percentage Change in LDL-C From the Initial Feeder Study Baseline | ORION-8 Baseline | -48.22 Percentage change in LDL-C |
| ORION-3 Rollover | Percentage Change in LDL-C From the Initial Feeder Study Baseline | Day 1080 / EOS | -49.95 Percentage change in LDL-C |